Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Press Releases

ELCC 2021 Virtual Press Release

Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer

Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from a study with the KRASG12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021.

Event Announcement

ESMO Targeted Anticancer Therapies Congress 2021, 1-2 March

The ESMO Targeted Anticancer Therapies Congress 2021, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.

Event Announcement

ESMO Immuno-Oncology Virtual Congress 2020

The ESMO Immuno-Oncology Congress 2020, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as a virtual meeting.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings